Myriad Genetics (MYGN -2.9%) shares slide after the U.S. Supreme Court agreed to hear a...
Monday, December 3, 2012, 2:59 PM ETMyriad Genetics (MYGN -2.9%) shares slide after the U.S. Supreme Court agreed to hear a challenge to the practice of issuing patents on human genes. Goldman Sachs cuts shares to Neutral from Buy on concerns that a final decision likely won't be reached before midyear. But Jefferies maintains its Buy rating, believing MYGN's patents should ultimately be upheld.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles